Showing results (431-440 of 446) with videos related to

Sort By:
Pageof 45
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|September 5, 2021
High seroprevalence of SARS-CoV-2 but low infection fatality ratio eight months after introduction in Nairobi, KenyaIsaac Ngere, Jeanette Dawa, Elizabeth Hunsperger, et al.
The Journal of Allergy and Clinical Immunology. Global|January 25, 2024
Passive antibody transfer from pregnant women to their fetus are maximized after SARS-CoV-2 vaccination irrespective of prior infectionCody J Lauritsen, Ivy V Trinh, Srushti P Desai, et al.
Science Translational Medicine|July 15, 2021
Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effectsMichelle Meyer, Bronwyn M Gunn, Delphine C Malherbe, et al.
Bone|December 3, 2014
Lack of prolidase causes a bone phenotype both in human and in mouseRoberta Besio, Silvia Maruelli, Roberta Gioia, et al.
The Journal of Allergy and Clinical Immunology. Global|April 9, 2024
Altered COVID-19 immunity in children with asthma by atopic statusSherry Tong, Jordan C Scott, Enwono Eyoh, et al.
Immunity|April 14, 2021
A Fc engineering approach to define functional humoral correlates of immunity against Ebola virusBronwyn M Gunn, Richard Lu, Matthew D Slein, et al.
Cell Host & Microbe|August 10, 2018
A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola VirusBronwyn M Gunn, Wen-Han Yu, Marcus M Karim, et al.
Scientific Reports|April 17, 2026
Antiretroviral therapy interferes with pseudovirus neutralization assays while Gag-specific T-cells influence mRNA vaccine outcomes in HIV patientsSean M Litwin, Ivy V Trinh, Shuangyi Bai, et al.
Biorxiv : the Preprint Server for Biology|November 25, 2020
An Engineered Antibody with Broad Protective Efficacy in Murine Models of SARS and COVID-19C Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Science (New York, N.Y.)|January 26, 2021
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibodyC Garrett Rappazzo, Longping V Tse, Chengzi I Kaku, et al.
Pageof 45